Chlorthalidone Injury Lawsuit Lawyers

Patients Who Used Recalled Chlorthalidone and Suffered Harm From Inadequately Controlled Blood Pressure or Other Medical Complications Can Get Answers By Contacting Our Firm.

What Parker Waichman LLP Found

• Two 2026 recalls encompass 25,027 bottles of chlorthalidone 25 mg tablets.
• All three recalled batches have an April 2027 expiration date.
• The stated reason for both recalls is failed dissolution specifications.
• Testing associated with the earlier recall found both an assay result below specification and a dissolution result below the acceptance criterion.
• A viable lawsuit generally requires more than proof that a patient received recalled pills. Evidence connecting the affected medication to an actual injury can be critical.

Thousands of Americans who depend on medication to control high blood pressure may have received chlorthalidone tablets from batches that did not meet established drug-quality specifications. In September 2026, Inventia Healthcare Limited initiated a nationwide recall involving 13,567 bottles of Chlorthalidone Tablets, USP, 25 mg after the tablets failed dissolution specifications. The affected product was distributed nationwide and identified as batch RISA24002, NDC 64980-599-01, with an April 2027 expiration date. The FDA classified the action as a Class II recall.

The September action was not the first chlorthalidone recall involving these 25 mg tablets in 2026. An earlier recall initiated in June involved another 11,460 bottles from batches RISA24001 and RISB24002. Those products also failed dissolution specifications and carry the same April 2027 expiration date. Combined, the two recalls encompass 25,027 bottles.

For patients, the issue deserves attention because chlorthalidone is not simply a medication taken for minor symptoms. It is an antihypertensive diuretic used to manage conditions including hypertension and certain forms of fluid retention. DailyMed identifies the recalled product’s source NDC as 64980-599 and describes chlorthalidone as an oral antihypertensive and diuretic.

A patient who faithfully takes prescribed medication ordinarily expects each tablet to provide the dosage and drug-release characteristics required by its approved specifications. When testing identifies an out-of-specification result, an important question is whether a patient received the intended therapeutic effect and, if not, whether reduced effectiveness contributed to an injury.

Which Chlorthalidone Tablets Were Recalled?

Patients and families investigating possible exposure should distinguish the recalled medication from other chlorthalidone products. The recalls do not mean that every chlorthalidone tablet sold in the United States is defective.

The September 2026 recall, identified as D-0852-2026, concerns 13,567 bottles of Chlorthalidone Tablets, USP, 25 mg manufactured by Inventia Healthcare Limited. The affected product is:

• Batch: RISA24002
• NDC: 64980-599-01
• Bottle size: 100 tablets
• Expiration: April 2027
• Recall initiated: September 3, 2026

The earlier recall, D-0610-2026, involves 11,460 bottles and includes:

• Batch RISA24001: NDC 64980-599-01, 100-tablet bottles, expiration April 2027.
• Batch RISB24002: NDC 64980-599-10, 1,000-tablet bottles, expiration April 2027.

Both recalls were nationwide.

The 25 mg product associated with source NDC 64980-599 is described on DailyMed as light yellow and round, with the imprint “103.” Physical appearance alone, however, should not be used to determine whether someone’s medication came from a recalled batch because other tablets may look similar. Pharmacy dispensing records, manufacturer information, NDC information, and lot or batch data can provide stronger evidence.

Why Was Chlorthalidone Recalled?

The stated reason is failed dissolution specifications. Dissolution testing evaluates the release of the active pharmaceutical ingredient from a dosage form under standardized laboratory conditions. For a medication intended to deliver a particular dose in a predictable manner, compliance with applicable specifications is an important component of pharmaceutical quality.

The information released concerning the earlier June recall provides additional insight into the quality-control issue.

According to a recall notice published by the California State Board of Pharmacy, an out-of-specification result occurred during 18-month long-term stability testing. The chlorthalidone assay was measured at 91.5%, below an approved specification of 92% to 108%. The mean dissolution result was 78%, with individual results ranging from 71% to 84%, while the acceptance criterion was not less than 80% of the labeled amount.

Those numbers are significant to an investigation because they provide more detail than simply saying a product was recalled.

At the same time, they should not be overstated. The June recall notice reported that a preliminary health-hazard assessment anticipated no impact on patient health and safety. FDA nevertheless classified the recalls as Class II. Under FDA terminology, Class II means exposure to the violative product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse consequences is remote.

Why Dissolution Problems Could Matter to a Patient

Prescription medications must perform predictably. A patient taking 25 mg of chlorthalidone every day may have no practical way to determine whether an individual tablet is meeting its expected pharmaceutical specifications.

That distinction becomes particularly important with medications used to manage chronic conditions.

Chlorthalidone is an antihypertensive diuretic. Its therapeutic purpose includes helping control blood pressure and reducing certain forms of fluid accumulation. A patient may take the drug for months or years while relying on it as one part of a broader treatment plan.

A dissolution failure does not establish that every recalled tablet delivered an inadequate dose, nor does it establish that every person who took one was harmed.

For litigation purposes, the important question is individualized causation.

If a particular patient was previously stable, received medication from a recalled batch, experienced an unexplained deterioration in blood-pressure control or another relevant medical problem during the exposure period, and subsequently suffered a documented injury, those facts may warrant closer investigation.

Medical records can become particularly important in establishing the chronology. Attorneys may examine blood-pressure readings before, during, and after the suspected exposure period, prescription histories, pharmacy records, medication changes, emergency treatment, hospital admissions, diagnostic testing, and physicians’ observations.

Potential Injuries Require Individual Medical Evaluation

Poorly controlled hypertension can have serious consequences, but it would be inaccurate to state that the recalled chlorthalidone caused any particular cardiovascular event simply because the patient happened to be taking the drug.

Causation must be evaluated case by case.

A legal investigation may be warranted when a person using medication from an affected batch subsequently experienced a significant deterioration in the condition the medication was intended to control or suffered an injury potentially related to that deterioration.

Depending on the patient’s underlying medical condition and the medical evidence, an investigation could examine events such as severe or uncontrolled hypertension, hypertensive emergencies, hospitalization, worsening fluid retention, or cardiovascular, kidney, or neurological complications.

However, many factors can affect blood pressure and cardiovascular health. Other medications, underlying disease, missed doses, diet, illness, kidney function, treatment changes, and preexisting cardiovascular risks may all become relevant.

This is why a drug-recall lawsuit should be based on medical evidence rather than assumptions drawn from the recall alone.

Does the FDA’s Class II Classification Mean the Drug Is Safe?

No recall classification should be interpreted as an individual medical diagnosis.

FDA defines a Class II recall as one involving a product whose use or exposure may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse consequences is remote. That classification distinguishes Class II recalls from Class I recalls, where there is a reasonable probability of serious adverse consequences or death.

It also does not mean every patient should immediately discontinue the medication.

FDA specifically advises that consumers can generally continue taking medication involved in a Class II recall unless the recalling company provides different instructions. FDA warns that, in some circumstances, abruptly stopping a medication may be more harmful than continuing it while the issue is addressed. Patients with questions should speak with their physician or pharmacist.

That consideration is especially important for medication prescribed to manage hypertension.

What Should Patients Taking Recalled Chlorthalidone Do?

Patients should not make treatment decisions solely because they read about a recall online. A physician or pharmacist can determine whether medication should be replaced and how treatment should continue.

Patients who believe they received recalled chlorthalidone can contact the pharmacy that dispensed their prescription and request information identifying the manufacturer, NDC, and available batch or lot information. They should compare that information with the affected products.

People who experienced an injury should also consider preserving evidence.

Do not discard prescription bottles, labels, remaining tablets, pharmacy paperwork, receipts, medication lists, or communications concerning the recall. Even if the original bottle is unavailable, pharmacy records may help identify what was dispensed and when.

Patients should also preserve records of relevant blood-pressure readings, including readings stored electronically in home monitors or health applications when available. A sequence of readings can sometimes be more informative than a single measurement because it may document when control of a condition changed.

What Evidence Could Be Important in a Chlorthalidone Recall Lawsuit?

Drug-injury litigation often depends on reconstructing what happened over time. An investigation may begin with proof of product identification. Lawyers may seek pharmacy dispensing records, prescription records, insurance claims, purchase information, photographs of medication containers, NDC information, lot numbers, and remaining medication.

The next issue is exposure. Records may help establish when the patient received the affected medication, how long it was taken, the prescribed dosage, and whether refills involved the same manufacturer or batch.

Medical causation requires a separate analysis. Medical records may establish the patient’s health before the exposure period and document subsequent changes in blood pressure, symptoms, treatment, emergency care, hospitalization, diagnostic findings, or medication adjustments.

The chronology can be especially important. A legal and medical review may ask whether a patient’s condition was stable before receiving the recalled medication, whether it worsened during the suspected exposure period, whether other explanations exist, and what occurred after the medication was changed or replaced.

Who May Have a Potential Chlorthalidone Recall Lawsuit?

Receiving recalled medication does not automatically mean someone has a viable personal injury claim. A stronger potential claim generally involves several components: evidence that the person actually received medication from an affected batch, evidence of exposure during a reasonably identifiable period, a documented injury or deterioration in health, and medical evidence capable of supporting a causal connection between the alleged product problem and that injury.

Potential defendants and causes of action will depend on the facts and the law of the applicable state. Pharmaceutical cases may involve claims concerning manufacturing defects, negligence, product liability, warranty, or other state-law theories.

FDA regulatory action itself does not create an automatic private federal lawsuit. Enforcement of the Federal Food, Drug, and Cosmetic Act is generally undertaken in the name of the United States, while pharmaceutical personal-injury claims frequently depend on applicable state law.

That distinction makes early case-specific legal analysis important.

What Compensation Could Be Available in a Chlorthalidone Lawsuit?

If liability and causation can be established, recoverable damages depend on applicable state law and the individual patient’s losses.

A claim may potentially seek compensation for medical expenses associated with the injury, including emergency treatment, hospitalization, physician visits, diagnostic procedures, medications, rehabilitation, and necessary future care. Lost earnings and diminished earning capacity may also be recoverable when an injury interferes with employment.

Non-economic damages may be available for physical pain, emotional suffering, disability, loss of normal activities, or diminished quality of life, depending on the jurisdiction and circumstances.

Cases involving a death require a different analysis. Surviving family members or an estate may have rights under applicable wrongful-death or survival statutes if legally sufficient evidence connects the medication problem to the death.

No particular category of damages is guaranteed merely because medication was recalled. Liability, causation, damages, defenses, and state-specific limitations must all be evaluated.

Why Patients Should Not Wait to Investigate a Potential Claim

Drug-injury cases can be evidence-intensive, and evidence becomes harder to obtain as time passes.

The prescription bottle may be discarded. Remaining pills may disappear. Pharmacies can change systems or retention practices. A patient may switch providers. Memories fade. Additional prescriptions can make it more difficult to determine precisely which manufacturer’s product was taken during a particular period.

There are also legal deadlines.

Statutes of limitations and related filing rules vary by state and by the legal theory involved. Determining the applicable deadline can require analyzing where the injury occurred, when the injury was discovered or reasonably should have been discovered, and other state-specific rules.

Anyone considering a claim should therefore avoid assuming that the existence of an ongoing FDA recall extends the time to file a lawsuit.

Chlorthalidone Recall Lawsuit FAQs

Do I Have a Lawsuit If I Took Recalled Chlorthalidone?

Not necessarily. Exposure to recalled medication and a legally compensable injury are different issues. A potential case generally becomes stronger when records confirm that you received an affected batch and medical evidence shows a significant injury or deterioration that can reasonably be connected to the medication’s alleged failure to perform as intended. Attorneys may need to review your pharmacy history, medical records, blood-pressure readings, underlying conditions, other medications, and timing of the injury before assessing a claim.

What If I No Longer Have My Prescription Bottle?

The absence of the bottle does not necessarily prevent an investigation. Your pharmacy may have records identifying the drug, dosage, manufacturer, NDC, dispensing date, and potentially lot or inventory information. Insurance and prescribing records can also help reconstruct your medication history. If you still possess any packaging or remaining tablets, preserve them rather than discarding them.

Can I Sue Simply Because My Medication Was Recalled?

A recall alone ordinarily does not establish a personal injury case. A plaintiff generally must establish the elements required by the applicable state-law claim, which can include product identification, defect or wrongful conduct, causation, and damages. The FDA recall may become relevant evidence, but it does not automatically prove that the recalled medication caused a particular patient’s injury.

What If My Blood Pressure Increased While I Was Taking the Recalled Tablets?

Documented changes in blood pressure could be important, particularly when records show that blood pressure had previously been controlled. However, elevated blood pressure has many possible causes. Attorneys and appropriate medical professionals may need to review your readings, medication history, compliance, medical conditions, treatment changes, and timing to determine whether the recalled medication could plausibly be related to the change.

How Long Do I Have to File a Chlorthalidone Lawsuit?

The deadline depends on the state and circumstances. Different jurisdictions apply different statutes of limitations, discovery rules, tolling provisions, and product-liability requirements. Waiting can also make evidence more difficult to preserve. A person who suffered an injury after using medication from an affected batch should have the applicable filing deadline evaluated promptly rather than assuming the recall date controls it.

Contact Parker Waichman LLP About a Chlorthalidone Recall Lawsuit

Patients take prescription blood-pressure medication with the expectation that the medicine they receive meets applicable quality specifications. When a medication is recalled because testing shows that it failed dissolution requirements, people who received affected batches deserve to know what happened and whether an injury may be connected to the recalled product.

Parker Waichman LLP is a national personal injury law firm representing people harmed by defective drugs and other dangerous products. The firm can investigate prescription and pharmacy records, determine whether medication came from an affected batch, review the circumstances surrounding an injury, and evaluate whether there may be grounds to pursue compensation.

If you or a family member used recalled chlorthalidone 25 mg tablets and suffered uncontrolled blood pressure, hospitalization, worsening medical problems, or another serious injury, Parker Waichman LLP offers a free consultation.

Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.